StockWatch
·

Navin Fluorine International Limited-$ Q2 FY27 Results

NAVINFLUORQ2 FY27 Results
Filing
Result:Very Good· Market: Surged#Broad based#Margin expansion#Record quarter

Outlook: Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue1.2K13.9%57.0%
Total Income1.2K11.7%55.3%
Expenditure854.7812.2%47.6%
PBT351.5610.4%78.0%
Net Profit269.2310.7%81.5%
OPM34.22%0.05pp1.76pp
NPM22.32%0.21pp3.22pp
EPS52.4810.6%80.6%
View full financials

Revenue +57% YoY and adjusted PAT +81% YoY with OPM expanding to 34.2% (at the top of management's 32-33% guided band) and no exceptional items — a clean, core-business-driven standout marking the highest quarterly PAT and revenue in six quarters.

NAVIN FLUORINE · Q2 FY27 · THE VERDICT

Margin beat + CDMO early, but capex makes this a Hold

Navin beat on EBITDA margins (34.2% vs. 32–33% guided) and posted 57% revenue growth, with CDMO USD100M target hit ahead of schedule. But the stock is priced at its all-time high, and near-term free cash flow faces a ₹700–1,000 crore annual capex siege. Long-term upside is not in doubt; near-term is a grind.

06 Nov 2026 · 6 min read
H1 revenue

₹2,236 Cr

+51% YoY

H1 PAT

₹513 Cr

+93% YoY

H1 EBITDA margin

34.2%

beat 32–33% ±1% guidance

NWC/NWD cycle

72 days

efficient working capital

Navin Fluorine delivered a genuinely strong H1: revenue raced ahead at 57% YoY growth in Q2, profit margins beat guidance by 66 basis points, and all three segments (HPP, Specialty Chemicals, CDMO) posted sequential and year-on-year momentum. The real tension is not whether the quarter was good — it was. The tension is whether this strong base is a stepping stone to the long-term upside (CDMO phase 2, Advanced Materials), or whether near-term free cash flow will drain under the weight of a ₹700–1,000 crore annual capex grind, while the stock sits nearly at its all-time high with valuations already baked in.

Where the margin beat came from

The 34.2% H1 EBITDA margin beat its 32–33% ±1% prior guidance. Management attributed this to three structural drivers, not a one-off tailwind: (1) operational leverage on a 51% H1 revenue ramp — fixed costs diluted; (2) capacity debottlenecking — MPP capacity commissioned in September 2026, R32 plant commissioning imminent, AHF utilization ramping at HPP; (3) pricing actions offsetting raw material inflation — HF, fluorspar, and sulfuric acid prices have risen, but pass-through contracts (Corteva, Soltice) and volume leverage held margins steady. Forex tailwind noted but positioned as a secondary factor. The operational efficiency lens is credible: a 57% revenue ramp with flat or lower-growth cost base is the classic margin-expansion recipe. However, this also signals that H2 normalization — if raw material tailwinds fade or pricing leverage compresses — could squeeze margins back toward guidance.

Management claims vs. what holds up

EBITDA margins 34.2%, beating guidance

Supported

H1 EBITDA margin 34.2% vs 32–33% ±1% prior guidance; OPM 34.2% sustained via operational efficiency (MPP debottlenecking, R32 ramp, AHF on play) + pricing actions offsetting cost inflation

CDMO USD100M run-rate target, achieved early

Supported

Achieved in Q2 on run-rate basis; management originally guided 'by FY27 end' — now flagged as arrived 2–3 quarters ahead of internal plan

All three segments delivered sequential growth

Supported

HPP (ref gas pricing advantage + Corteva/Soltice volumes), Specialty Chemicals (orchid business, Corteva growth, ₹350Cr+ targeting), CDMO (Fermion base + new molecule campaigns)

Gross profit resilience despite raw material inflation

Supported

OPM 34.2% held through pricing pass-through (contracts), volume leverage on 57% revenue ramp, and operational efficiency (not pricing alone or forex alone)

What changed on this call

Four material updates moved the dial: (1) Soltice HFO contract reset — extended from an original 4-year term to 11-year total visibility through 2032. Annual run-rate steps to USD45M vs. prior USD58M (pricing mechanism reflects market dynamics), but total potential jumps to USD180M on volume and pricing upside over the life of the deal. This is a strategic win: Soltice is the advanced-cooling play in a world moving away from HFC refrigerants. (2) CDMO inflection front-loaded — USD100M run-rate hit in Q2 (not by year-end as originally planned). Phase 2 cGMP-4 facility (₹125 crore capex) in progress; expected operational by end Q4 FY27. Once live, Navin targets ₹900–1,000 crore CDMO revenue by FY28–29 (3x asset turn on the Phase 1+2 capex base). (3) Specialty Chemicals now credibly targeted — management shifted from vague 'growth business' to a named ₹350 crore+ annual run-rate target by FY27 close. This signals confidence in product-market fit and pricing power in the chemicals franchise. (4) Capex frame quantified — ₹700–1,000 crore annually through FY28, split across Phase 2 cGMP-4 (₹125 Cr), Advanced Materials adoption capex (₹90 Cr to Q2 FY28), R32 ramp, and DRDO co-development projects. This is the capex grind that will pressure free cash flow.

The bull-bear ledger
  • Margin beat driven by operational efficiency (MPP debottlenecking, R32 ramp, AHF on play), not pricing windfall alone

  • CDMO USD100M target hit early; Phase 2 capex (₹125 Cr) in progress; 3–4 FDA readouts expected next 8–12 months

  • Soltice HFO contract extended 11 years (to 2032); USD180M potential on volume + pricing upside

  • Specialty Chemicals ₹350Cr+ target by FY27 end; broad-based segment growth (HPP, SC, CDMO all up)

  • Capex frame (₹700–1,000 Cr annually) will compress free cash flow through FY28; payback uncertain until Phase 2 revenue ramps

  • Customer concentration: HPP 60–65% of revenue; Corteva + Soltice ~40% of HPP; loss of either would be material

  • Raw material inflation (HF, fluorspar, sulfuric acid) could compress margins if pricing power weakens

  • Geopolitical volatility (Russia-Ukraine, Middle East) could disrupt supply chains and customer demand

Risks, ranked by how much they should concern a holder

Capex execution and near-term FCF pressure

High

₹700–1,000 Cr annual capex through FY28 will drain liquidity; delays on Phase 2 or Advanced Materials could defer revenue scaling and valuation upside. Working capital normalizing post-H1 seasonal boost could further tighten near-term cash.

Customer concentration in HPP segment

Medium-high

Loss of Corteva or Soltice could impact ₹400–500 Cr+ revenue (~40–50% of HPP). Mitigated by long-term contracts (Corteva to 2026, Soltice extended to 2032), but remains a structural concentration risk if end-markets weaken.

Raw material inflation compressing margins

Medium

HF, fluorspar, sulfuric acid prices elevated. If pricing power weakens (end-market demand softens, competitive pressure rises, or pass-through contracts lag inflation), EBITDA margins could compress below 30%. Management's efficiency gains could be offset.

CDMO molecule FDA approval delays

Medium

3–4 FDA readouts expected next 8–12 months are a key near-term catalyst. Regulatory delays beyond this window could push revenue scaling beyond FY28–29, deferring the Phase 2 capex payback and tightening near-term FCF further.

Geopolitical volatility disrupting supply and demand

Medium

Russia-Ukraine, Middle East tensions could disrupt supply of HF, fluorspar, and other raw materials. Refrigerant demand is cyclical to global capex; geopolitical shocks could crimp end-market demand for industrial cooling products.

How the street is positioned: The stock closed at ₹8,845 on 2026-11-05, just 1.17% below its all-time high of ₹8,949.5, and is trading above all three key moving averages (SMA20 ₹8,322.3, SMA50 ₹8,414.5, SMA200 ₹7,284.68). RSI is neutral at 60.2, but volume is increasing — a sign of accumulation or validation of the move. Domestically, DIIs edged higher to 28.46% ownership in Q1 FY27 (vs. 27.62% in Q4 FY26), a positive signal of institutional confidence; FIIs are flat at 23.73% (vs. 23.78% prior), and promoters steady at 27.08%. The combination — near-ATH price, flat FII, rising DII, increasing volume — suggests the market has priced the CDMO inflection and margin beats. There is limited downside from current valuations on a base-case execution (CDMO phase 2 on time, FDA readouts not all negative). However, there is also limited near-term upside: long-term value creation (FY28–29 EBITDA expansion) is still 18–24 months away, and near-term FCF will be compressed by capex. A holder at current prices is essentially betting on flawless Phase 2 execution and positive FDA catalysts. For new entrants, the risk-reward is balanced to slightly unfavorable — the upside is known (CDMO ₹900–1,000 Cr revenue, Advanced Materials commercialization), but the near-term grind (capex, FCF pressure) is also very real.

What to watch next
  • 1 · CDMO FDA readouts (Q3–Q4 FY27 and beyond)

    Management expects 3–4 molecule FDA readouts over the next 8–12 months. Two are in advanced trial stage with positive interim results; one China-approved molecule is on a fast-track FDA pathway. Positive readouts would de-risk the CDMO revenue ramp and justify Phase 2 capex. Negative outcomes or delays beyond the 8–12 month window would compress long-term EBITDA assumptions and force a reset of near-term FCF projections.

  • 2 · Phase 2 cGMP-4 commissioning (end Q4 FY27)

    ₹125 crore capex for Phase 2 dedicated CDMO facility; expected operational by end Q4 FY27. Full warehouse and ETP infrastructure to scale CDMO to ₹900–1,000 crore annual revenue by FY28–29. Any delay or cost overrun would extend the capex grind and defer cash generation. Track capex spend quarterly — if H2 FY27 capex exceeds the ₹350–400 Cr guidance run-rate, raise a red flag.

  • 3 · Advanced Materials adoption capex and commercialization (Q2 FY28)

    ₹90 crore capex in progress; expected commissioning by Q2 FY28. Navin will commercialize 4–5 lab-qualified products into a pharma market of ₹400+ crore (+ dual-use defense potential per DRDO co-dev). Early order visibility is encouraging, but volume ramp risk is real. By Q2 FY28, expect data on first-tranche sales, order pipeline, and pricing confidence.

Navin Fluorine is executing on plan. The quarter hit EBITDA margin guidance and beat the consensus print. CDMO inflection is real and arrived ahead of schedule. What's changed is confidence and clarity — management named a Specialty Chemicals target (₹350Cr+), quantified capex (₹700–1,000 Cr annually), and extended Soltice visibility to 2032. That's all credible.

But the stock is at its all-time high and near-term free cash flow faces a capex siege through FY28. Long-term value creation — Phase 2 revenue ramp, Advanced Materials commercialization — is compelling but 18–24 months away. The verdict is Hold. Do not chase at current prices; wait for Phase 2 commissioning and the first FDA readouts to de-risk the thesis. If execution falters (capex balloons, FDA delays, raw material margins compress), valuation will reset sharply.

The number to track from here: organic free cash flow. If quarterly FCF remains deeply negative through H2 FY27 due to capex, or if management signals further capex additions, the near-term story shifts from 'grind' to 'strain.' Hold and wait for clarity.

Informational and educational content only. Not investment advice.